


MRS2179 tetrasodium

Cat. No.:	HY-101308
CAS No.:	1454889-37-2
Molecular Formula:	C ₁₁ H ₁₃ N ₅ Na ₄ O ₉ P ₂
Molecular Weight:	513.16
Target:	P2Y Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a K _b of 102 nM and a pA ₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC ₅₀ =1.15 μM), P2X3 (12.9 μM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors ^{[1][2]} . MRS2179 tetrasodium inhibits platelet aggregation ^[3] .								
In Vivo	<p>MRS2179 (50 mg/kg; i.p.) prolongs the bleeding time^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>CL57BLr6 mice^[3]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Injection into the jugular vein of mice</td> </tr> <tr> <td>Result:</td> <td>The bleeding time, which reflects in vivo primary haemostasis, was significantly prolonged in MRS2179-treated mice, 30 s after injection of MRS2179.</td> </tr> </table>	Animal Model:	CL57BLr6 mice ^[3]	Dosage:	50 mg/kg	Administration:	Injection into the jugular vein of mice	Result:	The bleeding time, which reflects in vivo primary haemostasis, was significantly prolonged in MRS2179-treated mice, 30 s after injection of MRS2179.
Animal Model:	CL57BLr6 mice ^[3]								
Dosage:	50 mg/kg								
Administration:	Injection into the jugular vein of mice								
Result:	The bleeding time, which reflects in vivo primary haemostasis, was significantly prolonged in MRS2179-treated mice, 30 s after injection of MRS2179.								

REFERENCES

- [1]. Nandan E, et al. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. *J Med Chem.* 2000;43(5):829-842.
- [2]. von Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. *Pharmacol Ther.* 2006;110(3):415-432.
- [3]. Baurand A, Raboisson P, Freund M, et al. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. *Eur J Pharmacol.* 2001;412(3):213-221.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA